[Levosimendan - a 20-Year Experience]

Area of Science:

• Cardiology
• Pharmacology
• Intensive Care Medicine

Background:

• Levosimendan is a calcium sensitizer and ATP-dependent potassium channel opener approved for acute decompensated heart failure.
• It has been investigated for numerous conditions including cardiac surgery, right ventricular failure, pulmonary hypertension, and septic shock.

Purpose of the Study:

• To review the diverse physiological effects of levosimendan.
• To summarize findings from clinical trials evaluating levosimendan in various critical care settings.

Main Methods:

• Review of existing literature on levosimendan's pharmacology and clinical applications.
• Analysis of results from small studies and multicenter randomized placebo-controlled trials.

Main Results:

• Levosimendan demonstrates positive inotropy, improves ventriculoarterial coupling, enhances perfusion, and offers organ protection via mitochondrial effects.
• Despite promising effects in smaller studies, results from several large multicenter trials have been disappointing.

Conclusions:

• Levosimendan possesses a unique pharmacological profile with potential benefits in critical care.
• Further research is needed to clarify its role and optimize its use in specific patient populations, given the conflicting trial outcomes.